MedPath

Efficacy evaluation on switching to 50mg of minodronic acid hydrate in patients with osteoporosis

Not Applicable
Completed
Conditions
osteoporosis
Registration Number
JPRN-UMIN000012226
Lead Sponsor
Yokkaichi Social Insurance Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who have withdrawn their consent to participation in the study -Patients who discontinued their medication with minodronic acid hydrate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in bone mineral density
Secondary Outcome Measures
NameTimeMethod
-Changes in bone metabolic markers -Changes in pain symptoms -Changes in abdominal symptoms -Changes in patients will for medication
© Copyright 2025. All Rights Reserved by MedPath